glp 1 eye GLP-1 Receptor Agonists Could Reduce Risk of Glaucoma in Type 2 Diabetes Doctor Explains GLP 1 Blindness

Some important clinical considerations include: People with pre-existing diabetic retinopathy should be monitored closely, as rapid improvement in blood glucose control with semaglutide has been associated with temporary worsening of retinopathy complications [15] [16] GLP-1 receptor agonists may cause a modest increase in heart rate These medications should not be used in combination with DPP-4 inhibitors, as recommended by NICE NICE guidance recommends regular monitoring of HbA1c and body weight to assess treatment efficacy, with continuation of therapy dependent upon achieving meaningful clinical benefits within the first six months of treatment

How do you tailor the expected side effects to the individual patient

Long-term success depends on consistent medication use and maintaining healthy lifestyle habits

The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials